The Role Of Surgical Treatment In The Multidisciplinary Therapy For Hepatoblastoma

被引:5
作者
Yada, Keigo [1 ]
Ishibashi, Hiroki [1 ]
Mori, Hiroki [1 ]
Sato, Hirohiko [1 ]
Shimada, Mitsuo [1 ]
机构
[1] Univ Tokushima, Dept Pediat & Pediat Endoscop Surg, Tokushima, Tokushima 7708503, Japan
关键词
Hepatoblastoma; Pediatric; 18; Trisomy; Outcomes; Characteristics; Hepatectomy; PRETREATMENT PROGNOSTIC-FACTORS; PEDIATRIC-LIVER-TUMOR; CHILDHOOD HEPATOBLASTOMA; INTERNATIONAL SOCIETY; DOXORUBICIN; CISPLATIN; ONCOLOGY; TRISOMY-18; CHILDREN;
D O I
10.5754/hge14068
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The aim of this study was to evaluate the clinico-patholigical features and effects of multi-disciplinary therapy for pediatric patients with hepatoblastoma (HB). Methodology: Ten cases who underwent hepatectomy from 1996 to 2013 were studied. Our therapeutic protocol included neoadjuvant chemotherapy (NAC) + hepatectomy + adjuvant chemotherapy (AC). The regimens were CDDP+THP-ADR (n=2), CITA (n=1), PLADO (n=5), and CDDP(n = 1). One case with 18-trisomy underwent only hepatectomy. Medical records were reviewed to evaluate characteristics, the effects of chemotherapy and prognosis. Results: The median age at operation was 1.2 years (male: 7 and female: 3). PRETEXT classification was assigned to groups I (n=2), II (n=4), and III (n=4). 15 years overall survival and disease-free survival rates were 100% and 80%, respectively. Two cases, who had post-operative lung metastasis, underwent chemotherapy with or without complete resection of lung tumors. No further recurrence was observed in these two cases. One case with 18-trisomy underwent right hepatectomy for PRETEXT II HB and is still doing well 67 months after hepatectomy. Conclusion: It was found that multidisciplinary therapy based on surgery, including complete resections of recurrent lesions, offers long-term survival, even for cases which develop recurrent metastatic tumors or cases complicated with 18 trisomy.
引用
收藏
页码:553 / 556
页数:4
相关论文
共 14 条
[1]   Pretreatment prognostic factors for children with hepatoblastoma results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL 1 [J].
Brown, J ;
Perilongo, G ;
Shafford, E ;
Keeling, J ;
Pritchard, J ;
Brock, P ;
Dicks-Mireaux, C ;
Phillips, A ;
Vos, A ;
Plaschkes, J .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (11) :1418-1425
[2]   Pretreatment prognostic factors and treatment results in children with hepatoblastoma -: A report from the German Cooperative Pediatric Liver Tumor Study HB 94 [J].
Fuchs, J ;
Rydzynski, J ;
Von Schweinitz, D ;
Bode, U ;
Hecker, H ;
Weinel, P ;
Bürger, D ;
Harms, D ;
Erttmann, R ;
Oldhafer, K ;
Mildenberger, H .
CANCER, 2002, 95 (01) :172-182
[3]   Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT [J].
Hishiki, Tomoro ;
Matsunaga, Tadashi ;
Sasaki, Fumiaki ;
Yano, Michihiro ;
Ida, Kohmei ;
Horie, Hiroshi ;
Kondo, Satoshi ;
Watanabe, Ken-Ichiro ;
Oue, Takaharu ;
Tajiri, Tatsuro ;
Kamimatsuse, Arata ;
Ohnuma, Naomi ;
Hiyama, Eiso .
PEDIATRIC SURGERY INTERNATIONAL, 2011, 27 (01) :1-8
[4]   Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group [J].
Ortega, JA ;
Douglass, EC ;
Feusner, JH ;
Reynolds, M ;
Quinn, JJ ;
Finegold, MJ ;
Haas, JE ;
King, DR ;
Liu-Mares, W ;
Sensel, MG ;
Krailo, MD .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) :2665-2675
[5]   Risk-adapted treatment for childhood hepatoblastoma:: final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2 [J].
Perilongo, G ;
Shafford, E ;
Maibach, R ;
Aronson, D ;
Brugières, L ;
Brock, P ;
Childs, M ;
Czauderna, P ;
MacKinlay, G ;
Otte, JB ;
Pritchard, J ;
Rondelli, R ;
Scopinaro, M ;
Staalman, C ;
Plaschkes, J .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (03) :411-421
[6]   Hepatoblastoma clinical research: Lessons learned and future challenges [J].
Perilongo, Giorgio ;
Malogolowkin, Marcio ;
Feusner, James .
PEDIATRIC BLOOD & CANCER, 2012, 59 (05) :818-821
[7]   Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma [J].
Perilongo, Giorgio ;
Maibach, Rudolf ;
Shafford, Elisabeth ;
Brugieres, Laurence ;
Brock, Penelope ;
Morland, Bruce ;
de Camargo, Beatriz ;
Zsiros, Jozsef ;
Roebuck, Derek ;
Zimmermann, Arthur ;
Aronson, Daniel ;
Childs, Margaret ;
Widing, Eva ;
Laithier, Veronique ;
Plaschkes, Jack ;
Pritchard, Jon ;
Scopinaro, Marcello ;
MacKinlay, Gordon ;
Czauderna, Piotr .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (17) :1662-1670
[8]   Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach - Results of the first prospective study of the international society of pediatric oncology [J].
Pritchard, J ;
Brown, J ;
Shafford, E ;
Perilongo, G ;
Brock, P ;
Dicks-Mireaux, C ;
Keeling, J ;
Phillips, A ;
Vos, A ;
Plaschkes, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) :3819-3828
[9]   Population-based analyses of mortality in trisomy 13 and trisomy 18 [J].
Rasmussen, SA ;
Wong, LYC ;
Yang, QH ;
May, KM ;
Friedman, JM .
PEDIATRICS, 2003, 111 (04) :777-784
[10]   Hepatoblastoma: an oncological review [J].
Roebuck, DJ ;
Perilongo, G .
PEDIATRIC RADIOLOGY, 2006, 36 (03) :183-186